Global Paxlovid API Market Size study & Forecast, by Type (Purity =99%, Purity =99.5%), by Application (COVID-19 Oral Drugs, Research Reagents, Other) and Regional Analysis, 2023-2030

Global Paxlovid API Market Size study & Forecast, by Type (Purity ≥99%, Purity ≥99.5%), by Application (COVID-19 Oral Drugs, Research Reagents, Other) and Regional Analysis, 2023-2030

Global Paxlovid API Market is valued at approximately USD XXX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Paxlovid is a medicine that combines two antiviral drugs. It is authorized for the treatment of mild to moderate COVID-19 illnesses. The increasing demand for Paxlovid API in the pharmaceutical industry is the key factor responsible for market growth over the forecast period of 2023-2030.

The primary key factor anticipated to accelerate the growth of the Paxlovid API Market is the increasing demand in the pharmaceutical industry for the treatment of Covid illness. For instance- according to the World Health Organization, In Apr 2020, SARS-CoV-2 spread to over 209 countries and territories, with over 2,314,621 confirmed coronavirus cases recorded and 157,847 deaths globally. Also, increasing funding by the government for research and development for medications for COVID-19 and growing healthcare expenditure are creating a lucrative growth prospectus for the market over the forecast period. Moreover, the growing aging population and technological advancements create a positive outlook for the market. However, side effects of Paxlovid stifle market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Paxlovid API Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in terms of revenue owing to factors such as growing investments by the government in research & development in the biomedical and pharmaceuticals industry. Asia-Pacific is the fastest-growing region due to technology replacement and continuous innovations.

Major market player included in this report are:
Pfizer Inc
Merck & Co. Inc.
Ridgeback Biotherapeutics LP
Cipla Limited
Hetero Labs Limited
Sun Pharmaceutical Industries Ltd.
Laurus Labs Limited
Dr. Reddy's Laboratories Ltd.
Mylan N.V.
Torrent Pharmaceuticals Ltd.

Recent Developments in the Market:
In June 2022, Pfizer has invested $120 million to produce oral treatment for COVID-19, Paxlovid, with the expansion creating more than 250 high-skilled manufacturing jobs at the company’s site in Michigan.

Global Paxlovid API Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Type, Application, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Type:
Purity ≥99%
Purity ≥99.5%

By Application:
COVID-19 Oral Drugs
Research Reagents
Other

By Region:
North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Pfizer Inc
Merck & Co. Inc.
Ridgeback Biotherapeutics LP
Cipla Limited
Hetero Labs Limited
Sun Pharmaceutical Industries Ltd.
Laurus Labs Limited
Dr. Reddy's Laboratories Ltd.
Mylan N.V.
Torrent Pharmaceuticals Ltd.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.